Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
Stopped Due to lack of funding, phase II of study was not completed.
Conditions
- Non-Hodgkin's Lymphoma (NHL)
Interventions
- DRUG: Rituxan
- DRUG: motexafin gadolinium
- DRUG: 111Indium-Zevalin and 90Yttrium-Zevalin
Sponsor
Northwestern University
Collaborators